+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Thalassemia - Pipeline Review, H2 2019

  • ID: 4861698
  • Drug Pipelines
  • November 2019
  • Region: Global
  • 207 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Acceleron Pharma Inc
  • bluebird bio Inc
  • Editas Medicine Inc
  • Gamida Cell Ltd
  • Ionis Pharmaceuticals Inc
  • Orchard Therapeutics Plc
  • MORE
Thalassemia - Pipeline Review, H2 2019

Summary

The Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Thalassemia - Pipeline Review, H2 2019, provides an overview of the Thalassemia (Hematological Disorders) pipeline landscape.

Thalassemia is a group of inherited blood disorders that affect the body's ability to produce hemoglobin and red blood cells. Symptoms include fussiness, paleness, frequent infections, failure to thrive, poor appetite and jaundice. Predisposing factors include family history. Treatment includes blood transfusions and bone marrow transplant.

Report Highlights

The Publisher's Pharmaceutical and Healthcare latest pipeline guide Thalassemia - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Thalassemia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Thalassemia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Thalassemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 12, 7, 1, 15 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 3 and 1 molecules, respectively.

Thalassemia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from The Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Thalassemia (Hematological Disorders).
  • The pipeline guide reviews pipeline therapeutics for Thalassemia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Thalassemia (Hematological Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Thalassemia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Thalassemia (Hematological Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Thalassemia (Hematological Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Thalassemia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Acceleron Pharma Inc
  • bluebird bio Inc
  • Editas Medicine Inc
  • Gamida Cell Ltd
  • Ionis Pharmaceuticals Inc
  • Orchard Therapeutics Plc
  • MORE
Introduction
Thalassemia - Overview
Thalassemia - Therapeutics Development
Thalassemia - Therapeutics Assessment
Thalassemia - Companies Involved in Therapeutics Development
Thalassemia - Drug Profiles
Thalassemia - Dormant Projects
Thalassemia - Discontinued Products
Thalassemia - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Thalassemia, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Thalassemia - Pipeline by Acceleron Pharma Inc, H2 2019
Thalassemia - Pipeline by Agios Pharmaceuticals Inc, H2 2019
Thalassemia - Pipeline by Allife Medical Science and Technology Co Ltd, H2 2019
Thalassemia - Pipeline by Aruvant Sciences Inc, H2 2019
Thalassemia - Pipeline by ASC Therapeutics Inc, H2 2019
Thalassemia - Pipeline by Beam Therapeutics Inc, H2 2019
Thalassemia - Pipeline by bluebird bio Inc, H2 2019
Thalassemia - Pipeline by Cell Source Inc, H2 2019
Thalassemia - Pipeline by CRISPR Therapeutics AG, H2 2019
Thalassemia - Pipeline by CSL Ltd, H2 2019
Thalassemia - Pipeline by EdiGene Inc, H2 2019
Thalassemia - Pipeline by Editas Medicine Inc, H2 2019
Thalassemia - Pipeline by EmeraMed Ltd, H2 2019
Thalassemia - Pipeline by Epidestiny Inc, H2 2019
Thalassemia - Pipeline by Errant Gene Therapeutics LLC, H2 2019
Thalassemia - Pipeline by ExCellThera Inc, H2 2019
Thalassemia - Pipeline by Fulcrum Therapeutics Inc, H2 2019
Thalassemia - Pipeline by Gamida Cell Ltd, H2 2019
Thalassemia - Pipeline by Gilead Sciences Inc, H2 2019
Thalassemia - Pipeline by Imara Inc, H2 2019
Thalassemia - Pipeline by Incyte Corp, H2 2019
Thalassemia - Pipeline by Invenux LLC, H2 2019
Thalassemia - Pipeline by Ionis Pharmaceuticals Inc, H2 2019
Thalassemia - Pipeline by IRBM Science Park SpA, H2 2019
Thalassemia - Pipeline by La Jolla Pharmaceutical Company, H2 2019
Thalassemia - Pipeline by Merck & Co Inc, H2 2019
Thalassemia - Pipeline by Merganser Biotech Inc, H2 2019
Thalassemia - Pipeline by Nanomedic Inc, H2 2019
Thalassemia - Pipeline by Orchard Therapeutics Plc, H2 2019
Thalassemia - Pipeline by Phoenicia Biosciences Inc, H2 2019
Thalassemia - Pipeline by Protagonist Therapeutics Inc, H2 2019
Thalassemia - Pipeline by Rare Partners Srl, H2 2019
Thalassemia - Pipeline by Regenacy Pharmaceuticals LLC, H2 2019
Thalassemia - Pipeline by Sangamo Therapeutics Inc, H2 2019
Thalassemia - Pipeline by Sanquin Plasma Products BV, H2 2019
Thalassemia - Pipeline by Silence Therapeutics Plc, H2 2019
Thalassemia - Pipeline by Trucode Gene Repair Inc, H2 2019
Thalassemia - Pipeline by Vifor Pharma AG, H2 2019
Thalassemia - Dormant Projects, H2 2019
Thalassemia - Dormant Projects, H2 2019 (Contd..1), H2 2019
Thalassemia - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Thalassemia, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Acceleron Pharma Inc
  • Agios Pharmaceuticals Inc
  • Allife Medical Science and Technology Co Ltd
  • Aruvant Sciences Inc
  • ASC Therapeutics Inc
  • Beam Therapeutics Inc
  • bluebird bio Inc
  • Cell Source Inc
  • CRISPR Therapeutics AG
  • CSL Ltd
  • EdiGene Inc
  • Editas Medicine Inc
  • EmeraMed Ltd
  • Epidestiny Inc
  • Errant Gene Therapeutics LLC
  • ExCellThera Inc
  • Fulcrum Therapeutics Inc
  • Gamida Cell Ltd
  • Gilead Sciences Inc
  • Imara Inc
  • Incyte Corp
  • Invenux LLC
  • Ionis Pharmaceuticals Inc
  • IRBM Science Park SpA
  • La Jolla Pharmaceutical Company
  • Merck & Co Inc
  • Merganser Biotech Inc
  • Nanomedic Inc
  • Orchard Therapeutics Plc
  • Phoenicia Biosciences Inc
  • Protagonist Therapeutics Inc
  • Rare Partners Srl
  • Regenacy Pharmaceuticals LLC
  • Sangamo Therapeutics Inc
  • Sanquin Plasma Products BV
  • Silence Therapeutics Plc
  • Trucode Gene Repair Inc
  • Vifor Pharma AG
Note: Product cover images may vary from those shown
Adroll
adroll